Fortune 500 Pharma Cos Revenue/Profit/Employee Changes
（2010 over 2009)
| Rank | Company | F500 rank |
Revenue | % change from 2009 | Profits ($M) | % change from 2009 |
|---|---|---|---|---|---|---|
| 1 | Pfizer | 31 | 67,809.0 |
35.6 | 8,257.0 | -4.4 |
| 2 | J&J | 40 | 61,587.0 |
-0.5 | 13,334.0 |
8.7 |
| 3 | Merck | 53 | 45,987.0 | 67.7 | 861.0 | -93.3 |
| 4 | Abbott Labs | 69 | 35,166.7 | 14.3 | 4,626.2 | -19.5 |
| 5 | Eli Lilly | 115 | 23,076.0 | 5.7 | 5,069.5 | 17.1 |
| 6 | BMS | 131 | 19,484.0 | -9.9 | 3,102.0 | -70.8 |
| 7 | Amgen | 163 | 15,053.0 | 2.8 | 4,627.0 | 0.5 |
| 8 | Gilead | 299 | 7,949.4 | 13.4 | 2,901.3 | 10.1 |
| 9 | Mylan | 418 | 5,450.5 | 7.0 | 345.1 | 48.4 |
| 10 | Allergan | 457 | 4,919.4 | 9.2 | 0.6 | -99.9 |
| 11 | Biogen Idec | 476 | 4,716.4 | 7.7 | 1,005.3 | 3.6 |
| 12 | Genzyme | 487 | 4,535.9 | 0.5 | 422.1 | -0.0 |
| Rank | Company | EPS growth (%) | RTI growth 00-10(%) | RTI growth 10 (%) |
Employee | % Change from 2009 |
|---|---|---|---|---|---|---|
| 1 | Pfizer | 5.6 | -6.0 | 0.6 | 110,600 | -5.1 |
| 2 | J&J | 10.9 | 4.0 | -0.6 | 114,000 | -1.3 |
| 3 | Merck | -20.8 | -5.3 | 2.8 | 94,000 |
-6.0 |
| 4 | Abbott Labs | 5.2 | 3.1 | -8.2 | 91,440 |
25.5 |
| 5 | Eli Lilly | 5.1 | -6.3 | 3.8 | 38,350 | -5.0 |
| 6 | BMS | -2.7 | -5.2 | 10.2 | 27,000 | -3.6 |
| 7 | Amgen | 16.4 | -1.5 | -3.0 | 17,250 | 0.9 |
| 8 | Gilead | N.A. | 21.5 | -16.2 | 4,000 | 3.3 |
| 9 | Mylan | 2.6 | 7.1 | 14.7 | 13,000 | -7.1 |
| 10 | Allergan | -45.4 | 4.4 | 9.3 | 9,200 | 10.8 |
| 11 | Biogen Idec | 44.4 | 0.6 | 25.3 | 4,850 | 2.1 |
| 12 | Genzyme | 8.8 | 4.7 | 45.3 | 10,100 | -15.8 |
